Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose tissue + autologous platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Health Research Institute Hospital La Fe
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intradermal, Subcutaneous
01
Overview
This investigational regenerative medicine treatment consists of a combination of autologous adipose tissue and autologous platelet-rich plasma (PRP). Developed by the Instituto de Investigación Sanitaria La Fe in Valencia, Spain, the therapy is specifically designed to treat moderate to severe vulvar lichen sclerosus (VLS) in patients who have not responded adequately to first-line topical corticosteroids. The treatment involves harvesting fat tissue (providing adipose-derived stem cells) and blood (providing PRP) from the patient, which are then processed and injected into the affected vulvar subunits. The goal is to restore tissue elasticity and structure through the regenerative action of stem cells and concentrated growth factors. The modality was evaluated in the Phase II LIQUENIA clinical trial (NCT03961126) led by Dr. Patricia Gutiérrez Ontalvilla.
- Other names
- Tratamiento LiqueniaAdipose Tissue and PRP for Vulvar Lichen Sclerosusautologous platelet-rich plasma-Instituto de Investigacion Sanitaria La Fe-vulvar lichen sclerosus
Beyond the preview
Go deeper on autologous adipose tissue + autologous platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose tissue + autologous platelet-rich plasma.